Gossamer Bio Regains Full Control of Seralutinib as FDA NDA Submission Nears
Event summary
- Gossamer Bio plans to submit an NDA for seralutinib in PAH by September 2026, following a productive Pre-NDA Type B meeting with the FDA.
- The company reacquired worldwide rights to seralutinib from Chiesi, consolidating global control and simplifying its royalty structure.
- Gossamer's stockholders approved proposals related to a convertible note exchange and authorized a reverse stock split at a special meeting on July 14, 2026.
- As of June 30, 2026, Gossamer reported approximately $57 million in cash, cash equivalents, and marketable securities.
The big picture
Gossamer Bio's reacquisition of worldwide rights to seralutinib marks a strategic shift, consolidating control ahead of its planned NDA submission. This move aligns with broader industry trends where biopharmaceutical companies seek full operational autonomy to maximize the value of their lead assets. The company's financial restructuring and regulatory progress position it for potential commercial success in the competitive pulmonary hypertension market.
What we're watching
- Regulatory Timing
- Whether the FDA will accept Gossamer's NDA submission for seralutinib in PAH and provide an approval decision by Q3 2027.
- Financial Flexibility
- How Gossamer will utilize its $57 million cash position to fund operations until potential commercialization of seralutinib.
- Market Positioning
- The pace at which Gossamer can establish seralutinib as a first-in-class therapy in PAH and expand into other indications like PH-ILD.